- Home
- CBNK vs DRUG Comparison
CBNK vs DRUG Comparison
Compare CBNK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNK
- DRUG
- Stock Information
- Founded
- CBNK 1974
- DRUG 2019
- Country
- CBNK United States
- DRUG United States
- Employees
- CBNK N/A
- DRUG N/A
- Industry
- CBNK Major Banks
- DRUG Pharmaceuticals and Biotechnology
- Sector
- CBNK Finance
- DRUG Health Care
- Exchange
- CBNK Nasdaq
- DRUG Nasdaq
- Market Cap
- CBNK 501.8M
- DRUG 484.7M
- IPO Year
- CBNK 2018
- DRUG N/A
- Fundamental
- Price
- CBNK $29.32
- DRUG $61.38
- Analyst Decision
- CBNK Hold
- DRUG Strong Buy
- Analyst Count
- CBNK 1
- DRUG 9
- Target Price
- CBNK $35.00
- DRUG $81.67
- AVG Volume (30 Days)
- CBNK 46.5K
- DRUG 122.1K
- Earning Date
- CBNK 10-24-2025
- DRUG 08-11-2025
- Dividend Yield
- CBNK 1.63%
- DRUG N/A
- EPS Growth
- CBNK 11.33
- DRUG N/A
- EPS
- CBNK 2.69
- DRUG N/A
- Revenue
- CBNK $205,155,000.00
- DRUG N/A
- Revenue This Year
- CBNK $47.22
- DRUG N/A
- Revenue Next Year
- CBNK $7.72
- DRUG N/A
- P/E Ratio
- CBNK $10.98
- DRUG N/A
- Revenue Growth
- CBNK 30.26
- DRUG N/A
- 52 Week Low
- CBNK $24.12
- DRUG $23.18
- 52 Week High
- CBNK $36.40
- DRUG $70.23
- Technical
- Relative Strength Index (RSI)
- CBNK 39.66
- DRUG 54.32
- Support Level
- CBNK $28.25
- DRUG $59.85
- Resistance Level
- CBNK $30.07
- DRUG $69.70
- Average True Range (ATR)
- CBNK 0.72
- DRUG 6.39
- MACD
- CBNK 0.07
- DRUG -0.39
- Stochastic Oscillator
- CBNK 47.21
- DRUG 57.55
About CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.